8-K: Gain Therapeutics Accelerates Parkinson's Study Biomarker Readout, Extends Phase 1b Enrollment

Gain Therapeutics, Inc. announced accelerated biomarker analysis for its GT-02287 Parkinson's disease Phase 1b study, with full 90-day results now expected in Q4 2025, despite an initial protocol delay.

Summary

• Gain Therapeutics, Inc. provided an update on its Phase 1b clinical study for GT-02287 in people with Parkinson's Disease with or without a GBA1 mutation.
• The study, which aimed to enroll 15-20 participants, has successfully reached 16 participants as of June 30, 2025.
• An independent data monitoring committee recently met and recommended continuing the study with no changes in dose level, concluding no serious treatment emergent adverse events have occurred.
• Faster-than-anticipated enrollment means all participants will complete their 90-day visit in time to facilitate biomarker analysis of all cerebrospinal fluid (CSF) samples by Q4 2025, which is earlier than the original Q1 2026 projection.
• Full results on 90-day biomarker evidence from all CSF and blood samples are now expected together during Q4 2025, also earlier than originally planned.
• The screening window for participants in Australia has been extended through July 31, 2025, to facilitate continued interest.
• The company is planning to approach local health authorities in Australia to extend the dosing period of the Phase 1b beyond the currently allowed 90-day period.
• Long-term chronic toxicology studies required to support this extension of dosing are nearing completion, with an update expected before the end of Q3 2025.
• The extension of the Phase 1b is believed to better inform Phase 2 protocol design and planning for early 2026.

Sentiment

Score: 8

Explanation: The document indicates positive progress in the Phase 1b clinical study for GT-02287, including faster-than-anticipated enrollment, a positive safety review by an independent committee, and an accelerated timeline for key biomarker results. While there was an initial protocol delay, the overall outlook presented is favorable for the study's progression.

Positives

• An independent data monitoring committee recommended continuing the study with no changes in dose level.
• No serious treatment emergent adverse events have occurred in the study.
• Enrollment reached 16 participants, which was faster than anticipated.
• Biomarker analysis of all cerebrospinal fluid (CSF) samples from 90-day visits is now expected by Q4 2025, accelerating from the original Q1 2026 timeline.
• Full results on 90-day biomarker evidence from all CSF and blood samples are expected together during Q4 2025, which is earlier than originally planned.
• The extension of the Phase 1b study is expected to better inform Phase 2 protocol design and planning for early 2026.

Negatives

• The Phase 1b study experienced an initial two-month delay in protocol implementation.

Future Outlook

The company anticipates providing full results on 90-day biomarker evidence from all CSF and blood samples together during Q4 2025, which is earlier than originally planned. They also plan to extend the dosing period of the Phase 1b study beyond 90 days, pending approval from local health authorities in Australia and completion of long-term chronic toxicology studies. This extension is expected to better inform Phase 2 protocol design and planning for early 2026.

Management Comments

• The Company believes that the extension of the Phase 1b will also better inform Phase 2 protocol design and planning for early 2026.

Industry Context

The update relates to the development of a therapeutic for Parkinson's Disease, a significant neurodegenerative disorder with high unmet medical needs. Successful progression of clinical trials, especially with positive safety profiles and accelerated data readouts, is crucial for companies in the biotechnology and pharmaceutical sectors, particularly those focused on central nervous system disorders. The focus on GBA1 mutation suggests a targeted approach within the Parkinson's patient population.

Stakeholder Impact

• Shareholders: Positive impact due to accelerated clinical trial progress, positive safety data, and earlier expected data readout, potentially de-risking the asset and providing earlier clarity on its potential.
• Patients/Clinicians: Positive impact due to continued study, potential for extended dosing, and progress towards a new treatment for Parkinson's Disease.
• Employees: Positive impact from successful clinical trial progression.

Next Steps

• All 16 participants to reach their 90-day visit for biomarker analysis.
• Provide full results on 90-day biomarker evidence from all CSF and blood samples during Q4 2025.
• Extend the screening window for participants through July 31, 2025.
• Approach local health authorities in Australia to extend the dosing period of the Phase 1b beyond 90 days.
• Complete long-term chronic toxicology studies to support the dosing extension.
• Provide an update on the progress of the dosing extension before the end of Q3 2025.
• Inform Phase 2 protocol design and planning for early 2026.

Key Dates

Recommendation

Keywords

Parkinson's Disease, GT-02287, Phase 1b clinical study, Biomarker analysis, Cerebrospinal fluid (CSF), GBA1 mutation, Clinical trial, Drug development, Neurodegenerative disease, Gain Therapeutics